TheraSource LLC is a biopharmaceutical company developing novel anti-inflammatory therapeutics for the treatment of human diseases. Spun out of the Feinstein Institute, the firm has demonstrated the efficacy of several newly-discovered molecules in preclinical studies of various medical conditions including ischemic acute kidney injury (AKI), inflammatory bowel disease (IBD), acute ischemic stroke, acute radiation syndrome, shock and sepsis, leading to >250 peer-reviewed publications. The firm's lead drug for development and commercialization for sepsis therapy usage is MFG-E8. In 2016 the firm was in receipt of a three-year non-SBIR grant from NIH to develop a treatment for radiation poisoning an area of inestigation that. in collaboration with the Feinstein institute. has been underway in the firm for several years
